Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Factor XIa inhibition with asundexian after acute non-cardioembolic ischaemic stroke (PACIFIC-Stroke): an international, randomised, double-blind, placebo-controlled, phase 2b trial

A. Shoamanesh, H. Mundl, EE. Smith, J. Masjuan, I. Milanov, T. Hirano, A. Agafina, B. Campbell, V. Caso, JL. Mas, Q. Dong, P. Turcani, H. Christensen, JM. Ferro, R. Veltkamp, R. Mikulik, GM. De Marchis, T. Robinson, R. Lemmens, A. Stepien, S....

. 2022 ; 400 (10357) : 997-1007. [pub] 20220902

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články, randomizované kontrolované studie

Perzistentní odkaz   https://www.medvik.cz/link/bmc22024356
E-zdroje Online Plný text

NLK ProQuest Central od 1992-01-04 do Před 3 měsíci
Nursing & Allied Health Database (ProQuest) od 1992-01-04 do Před 3 měsíci
Health & Medicine (ProQuest) od 1992-01-04 do Před 3 měsíci
Family Health Database (ProQuest) od 1992-01-04 do Před 3 měsíci
Psychology Database (ProQuest) od 1992-01-04 do Před 3 měsíci
Health Management Database (ProQuest) od 1992-01-04 do Před 3 měsíci
Public Health Database (ProQuest) od 1992-01-04 do Před 3 měsíci

BACKGROUND: Asundexian (Bayer AG, Leverkusen, Germany), an oral small molecule factor XIa (FXIa) inhibitor, might prevent thrombosis without increasing bleeding. Asundexian's effect for secondary prevention of recurrent stroke is unknown. METHODS: In this randomised, double-blind, placebo-controlled, phase 2b dose-finding trial (PACIFIC-Stroke), patients with acute (within 48 h) non-cardioembolic ischaemic stroke were recruited from 196 hospitals in 23 countries. Patients were eligible if they were aged 45 years or older, to be treated with antiplatelet therapy, and able to have a baseline MRI (either before or within 72 h of randomisation). Eligible participants were randomly assigned (1:1:1:1), using an interactive web-based response system and stratified according to anticipated antiplatelet therapy (single vs dual), to once daily oral asundexian (BAY 2433334) 10 mg, 20 mg, or 50 mg, or placebo in addition to usual antiplatelet therapy, and were followed up during treatment for 26-52 weeks. Brain MRIs were obtained at study entry and at 26 weeks or as soon as possible after treatment discontinuation. The primary efficacy outcome was the dose-response effect on the composite of incident MRI-detected covert brain infarcts and recurrent symptomatic ischaemic stroke at or before 26 weeks after randomisation. The primary safety outcome was major or clinically relevant non-major bleeding as defined by International Society on Thrombosis and Haemostasis criteria. The efficacy outcome was assessed in all participants assigned to treatment, and the safety outcome was assessed in all participants who received at least one dose of study treatment. This study is registered with ClinicalTrials.gov, NCT04304508, and is now complete. FINDINGS: Between June 15, 2020, and July 22, 2021, 1880 patients were screened and 1808 participants were randomly assigned to asundexian 10 mg (n=455), 20 mg (n=450), or 50 mg (n=447), or placebo (n=456). Mean age was 67 years (SD 10) and 615 (34%) participants were women, 1193 (66%) were men, 1505 (83%) were White, and 268 (15%) were Asian. The mean time from index stroke to randomisation was 36 h (SD 10) and median baseline National Institutes of Health Stroke Scale score was 2·0 (IQR 1·0-4·0). 783 (43%) participants received dual antiplatelet treatment for a mean duration of 70·1 days (SD 113·4) after randomisation. At 26 weeks, the primary efficacy outcome was observed in 87 (19%) of 456 participants in the placebo group versus 86 (19%) of 455 in the asundexian 10 mg group (crude incidence ratio 0·99 [90% CI 0·79-1·24]), 99 (22%) of 450 in the asundexian 20 mg group (1·15 [0·93-1·43]), and 90 (20%) of 447 in the asundexian 50 mg group (1·06 [0·85-1·32]; t statistic -0·68; p=0·80). The primary safety outcome was observed in 11 (2%) of 452 participants in the placebo group versus 19 (4%) of 445 in the asundexian 10 mg group, 14 (3%) of 446 in the asundexian 20 mg group, and 19 (4%) of 443 in the asundexian 50 mg group (all asundexian doses pooled vs placebo hazard ratio 1·57 [90% CI 0·91-2·71]). INTERPRETATION: In this phase 2b trial, FXIa inhibition with asundexian did not reduce the composite of covert brain infarction or ischaemic stroke and did not increase the composite of major or clinically relevant non-major bleeding compared with placebo in patients with acute, non-cardioembolic ischaemic stroke. FUNDING: Bayer AG.

1st Department of Neurology Medical Faculty Comenius University Bratislava Slovakia

Bayer AG Wuppertal Germany

Bayer US Pharmaceuticals Whippany NJ USA

Clinical Research Department City Hospital 40 Saint Petersburg Russia

College of Life Sciences University of Leicester Leicester UK

DE Clinical Center Health Service Units Clinics Department of Neurology University of Debrecen Debrecen Hungary

Departamento de Medicina Facultad de Medicina Universidad de Alcalá IRYCIS RICORS ICTUS Madrid Spain

Department of Clinical Neurosciences Hotchkiss Brain Institute Cumming School of Medicine University of Calgary Calgary AB Canada

Department of Clinical Sciences Lund Lund University Lund Sweden

Department of Medicine and Neurology Melbourne Brain Centre at the Royal Melbourne Hospital University of Melbourne Parkville VIC Australia

Department of Medicine McMaster University Population Health Research Institute Hamilton ON Canada

Department of Neurology Amsterdam UMC University of Amsterdam Amsterdam Netherlands

Department of Neurology and Rehabilitation Sciences University of Cincinnati Cincinnati OH USA

Department of Neurology and Stroke Center University Hospital of Basel and University of Basel Basel Switzerland

Department of Neurology GHU Paris Hôpital Sainte Anne Université Paris Cité Inserm U1266 Paris France

Department of Neurology Huashan Hospital Fudan University Shanghai China

Department of Neurology Medical University of Vienna Vienna Austria

Department of Neurology Military Institute of Medicine Warsaw Poland

Department of Neurology Skåne University Hospital Lund Sweden

Department of Neurology University Hospital of Copenhagen Bispebjerg Denmark

Department of Neurology University Hospitals Leuven Leuven Belgium

Department of Neurosciences Experimental Neurology KU Leuven University of Leuven Leuven Belgium

Department of Radiology Hotchkiss Brain Institute Cumming School of Medicine University of Calgary Calgary AB Canada

Department of Statistics McMaster University Population Health Research Institute Hamilton ON Canada

Department of Stroke and Cerebrovascular Medicine School of Medicine Kyorin University Tokyo Japan

Division of Clinical Neurosciences University of Turku Turku Finland

Division of Neurology McMaster University Population Health Research Institute Hamilton ON Canada

Instituto de Medicina Molecular João Lobo Antunes Faculdade de Medicina Universidade de Lisboa Lisbon Portugal

International Clinical Research Center and Neurology Department St Anne's University Hospital Brno Czech Republic

Medical Faculty Masaryk University Brno Czech Republic

Medical University University Hospital for Neurology and Psychiatry St Naum Sofia Bulgaria

Neurology Department Alfried Krupp Hospital Essen Germany

Neurology Department Hospital Universitario Ramón y Cajal Madrid Spain

Statistics and Data Insights Bayer AG Berlin Germany

Stroke Unit Santa Maria della Misericordia Hospital University of Perugia Perugia Italy

TA Thrombosis and Vascular Medicine Bayer AG Wuppertal Germany

VIB KU Leuven Center for Brain and Disease Research Leuven Belgium

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22024356
003      
CZ-PrNML
005      
20221031100314.0
007      
ta
008      
221017s2022 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1016/S0140-6736(22)01588-4 $2 doi
035    __
$a (PubMed)36063821
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Shoamanesh, Ashkan $u Division of Neurology, McMaster University, Population Health Research Institute, Hamilton, ON, Canada. Electronic address: ashkan.shoamanesh@phri.ca
245    10
$a Factor XIa inhibition with asundexian after acute non-cardioembolic ischaemic stroke (PACIFIC-Stroke): an international, randomised, double-blind, placebo-controlled, phase 2b trial / $c A. Shoamanesh, H. Mundl, EE. Smith, J. Masjuan, I. Milanov, T. Hirano, A. Agafina, B. Campbell, V. Caso, JL. Mas, Q. Dong, P. Turcani, H. Christensen, JM. Ferro, R. Veltkamp, R. Mikulik, GM. De Marchis, T. Robinson, R. Lemmens, A. Stepien, S. Greisenegger, R. Roine, L. Csiba, P. Khatri, J. Coutinho, AG. Lindgren, AM. Demchuk, P. Colorado, B. Kirsch, C. Neumann, L. Heenan, L. Xu, SJ. Connolly, RG. Hart, PACIFIC-Stroke Investigators
520    9_
$a BACKGROUND: Asundexian (Bayer AG, Leverkusen, Germany), an oral small molecule factor XIa (FXIa) inhibitor, might prevent thrombosis without increasing bleeding. Asundexian's effect for secondary prevention of recurrent stroke is unknown. METHODS: In this randomised, double-blind, placebo-controlled, phase 2b dose-finding trial (PACIFIC-Stroke), patients with acute (within 48 h) non-cardioembolic ischaemic stroke were recruited from 196 hospitals in 23 countries. Patients were eligible if they were aged 45 years or older, to be treated with antiplatelet therapy, and able to have a baseline MRI (either before or within 72 h of randomisation). Eligible participants were randomly assigned (1:1:1:1), using an interactive web-based response system and stratified according to anticipated antiplatelet therapy (single vs dual), to once daily oral asundexian (BAY 2433334) 10 mg, 20 mg, or 50 mg, or placebo in addition to usual antiplatelet therapy, and were followed up during treatment for 26-52 weeks. Brain MRIs were obtained at study entry and at 26 weeks or as soon as possible after treatment discontinuation. The primary efficacy outcome was the dose-response effect on the composite of incident MRI-detected covert brain infarcts and recurrent symptomatic ischaemic stroke at or before 26 weeks after randomisation. The primary safety outcome was major or clinically relevant non-major bleeding as defined by International Society on Thrombosis and Haemostasis criteria. The efficacy outcome was assessed in all participants assigned to treatment, and the safety outcome was assessed in all participants who received at least one dose of study treatment. This study is registered with ClinicalTrials.gov, NCT04304508, and is now complete. FINDINGS: Between June 15, 2020, and July 22, 2021, 1880 patients were screened and 1808 participants were randomly assigned to asundexian 10 mg (n=455), 20 mg (n=450), or 50 mg (n=447), or placebo (n=456). Mean age was 67 years (SD 10) and 615 (34%) participants were women, 1193 (66%) were men, 1505 (83%) were White, and 268 (15%) were Asian. The mean time from index stroke to randomisation was 36 h (SD 10) and median baseline National Institutes of Health Stroke Scale score was 2·0 (IQR 1·0-4·0). 783 (43%) participants received dual antiplatelet treatment for a mean duration of 70·1 days (SD 113·4) after randomisation. At 26 weeks, the primary efficacy outcome was observed in 87 (19%) of 456 participants in the placebo group versus 86 (19%) of 455 in the asundexian 10 mg group (crude incidence ratio 0·99 [90% CI 0·79-1·24]), 99 (22%) of 450 in the asundexian 20 mg group (1·15 [0·93-1·43]), and 90 (20%) of 447 in the asundexian 50 mg group (1·06 [0·85-1·32]; t statistic -0·68; p=0·80). The primary safety outcome was observed in 11 (2%) of 452 participants in the placebo group versus 19 (4%) of 445 in the asundexian 10 mg group, 14 (3%) of 446 in the asundexian 20 mg group, and 19 (4%) of 443 in the asundexian 50 mg group (all asundexian doses pooled vs placebo hazard ratio 1·57 [90% CI 0·91-2·71]). INTERPRETATION: In this phase 2b trial, FXIa inhibition with asundexian did not reduce the composite of covert brain infarction or ischaemic stroke and did not increase the composite of major or clinically relevant non-major bleeding compared with placebo in patients with acute, non-cardioembolic ischaemic stroke. FUNDING: Bayer AG.
650    _2
$a senioři $7 D000368
650    _2
$a antikoagulancia $x terapeutické užití $7 D000925
650    12
$a ischemie mozku $x farmakoterapie $x prevence a kontrola $7 D002545
650    _2
$a dvojitá slepá metoda $7 D004311
650    _2
$a faktor XIa $7 D015945
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a krvácení $x chemicky indukované $x farmakoterapie $7 D006470
650    _2
$a lidé $7 D006801
650    12
$a ischemická cévní mozková příhoda $7 D000083242
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a inhibitory agregace trombocytů $x terapeutické užití $7 D010975
650    12
$a cévní mozková příhoda $x farmakoterapie $x prevence a kontrola $7 D020521
650    12
$a trombóza $7 D013927
650    _2
$a výsledek terapie $7 D016896
655    _2
$a časopisecké články $7 D016428
655    _2
$a randomizované kontrolované studie $7 D016449
700    1_
$a Mundl, Hardi $u TA Thrombosis and Vascular Medicine, Bayer AG, Wuppertal, Germany
700    1_
$a Smith, Eric E $u Department of Clinical Neurosciences, Hotchkiss Brain Institute, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada; Department of Radiology, Hotchkiss Brain Institute, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada
700    1_
$a Masjuan, Jaime $u Neurology Department, Hospital Universitario Ramón y Cajal, Madrid, Spain; Departamento de Medicina, Facultad de Medicina, Universidad de Alcalá, IRYCIS, RICORS-ICTUS, Madrid, Spain
700    1_
$a Milanov, Ivan $u Medical University, University Hospital for Neurology and Psychiatry "St Naum", Sofia, Bulgaria
700    1_
$a Hirano, Teruyuki $u Department of Stroke and Cerebrovascular Medicine, School of Medicine, Kyorin University, Tokyo, Japan
700    1_
$a Agafina, Alina $u Clinical Research Department, City Hospital #40, Saint Petersburg, Russia
700    1_
$a Campbell, Bruce $u Department of Medicine and Neurology, Melbourne Brain Centre at the Royal Melbourne Hospital, University of Melbourne, Parkville, VIC, Australia
700    1_
$a Caso, Valeria $u Stroke Unit, Santa Maria della Misericordia Hospital, University of Perugia, Perugia, Italy
700    1_
$a Mas, Jean-Louis $u Department of Neurology, GHU Paris, Hôpital Sainte-Anne, Université Paris-Cité, Inserm U1266, Paris, France
700    1_
$a Dong, Qiang $u Department of Neurology, Huashan Hospital, Fudan University, Shanghai, China
700    1_
$a Turcani, Peter $u 1st Department of Neurology, Medical Faculty, Comenius University, Bratislava, Slovakia
700    1_
$a Christensen, Hanne $u Department of Neurology, University Hospital of Copenhagen, Bispebjerg, Denmark
700    1_
$a Ferro, Jose M $u Instituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal
700    1_
$a Veltkamp, Roland $u Neurology Department, Alfried-Krupp Hospital, Essen, Germany
700    1_
$a Mikulik, Robert $u International Clinical Research Center and Neurology Department, St Anne's University Hospital, Brno, Czech Republic; Medical Faculty, Masaryk University, Brno, Czech Republic
700    1_
$a De Marchis, Gian Marco $u Department of Neurology and Stroke Center, University Hospital of Basel and University of Basel, Basel, Switzerland
700    1_
$a Robinson, Thompson $u College of Life Sciences, University of Leicester, Leicester, UK
700    1_
$a Lemmens, Robin $u Department of Neurosciences, Experimental Neurology, KU Leuven - University of Leuven, Leuven, Belgium; VIB-KU Leuven Center for Brain and Disease Research, Leuven, Belgium; Department of Neurology, University Hospitals Leuven, Leuven, Belgium
700    1_
$a Stepien, Adam $u Department of Neurology, Military Institute of Medicine, Warsaw, Poland
700    1_
$a Greisenegger, Stefan $u Department of Neurology, Medical University of Vienna, Vienna, Austria
700    1_
$a Roine, Risto $u Division of Clinical Neurosciences, University of Turku, Turku, Finland
700    1_
$a Csiba, Laszlo $u DE Clinical Center (DEKK), Health Service Units, Clinics, Department of Neurology, University of Debrecen, Debrecen, Hungary
700    1_
$a Khatri, Pooja $u Department of Neurology and Rehabilitation Sciences, University of Cincinnati, Cincinnati, OH, USA
700    1_
$a Coutinho, Jonathan $u Department of Neurology, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands
700    1_
$a Lindgren, Arne G $u Department of Clinical Sciences Lund (Neurology), Lund University, Lund, Sweden; Department of Neurology, Skåne University Hospital, Lund, Sweden
700    1_
$a Demchuk, Andrew M $u Department of Clinical Neurosciences, Hotchkiss Brain Institute, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada; Department of Radiology, Hotchkiss Brain Institute, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada
700    1_
$a Colorado, Pablo $u Bayer US Pharmaceuticals, Whippany, NJ, USA
700    1_
$a Kirsch, Bodo $u Statistics and Data Insights, Bayer AG, Berlin, Germany
700    1_
$a Neumann, Christoph $u Bayer AG, Wuppertal, Germany
700    1_
$a Heenan, Laura $u Department of Statistics, McMaster University, Population Health Research Institute, Hamilton, ON, Canada
700    1_
$a Xu, Lizhen $u Department of Statistics, McMaster University, Population Health Research Institute, Hamilton, ON, Canada
700    1_
$a Connolly, Stuart J $u Department of Medicine, McMaster University, Population Health Research Institute, Hamilton, ON, Canada
700    1_
$a Hart, Robert G $u Division of Neurology, McMaster University, Population Health Research Institute, Hamilton, ON, Canada
710    2_
$a PACIFIC-Stroke Investigators
773    0_
$w MED00010161 $t Lancet $x 1474-547X $g Roč. 400, č. 10357 (2022), s. 997-1007
856    41
$u https://pubmed.ncbi.nlm.nih.gov/36063821 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20221017 $b ABA008
991    __
$a 20221031100311 $b ABA008
999    __
$a ok $b bmc $g 1854209 $s 1175646
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2022 $b 400 $c 10357 $d 997-1007 $e 20220902 $i 1474-547X $m Lancet $n Lancet $x MED00010161
LZP    __
$a Pubmed-20221017

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...